Skip to content

How quickly are novel cancer therapies adopted after FDA approval and incorporation into EHR-embedded clinical decision support tools?

Published

October 2023

Citation

Maniago RL, Ricottone M, Sheikh A, et al. How quickly are novel cancer therapies adopted after FDA approval and incorporation into EHR-embedded clinical decision support tools? A description of ordering patterns between users and non-users of an EHR-embedded oncology CDS tool. Poster presented at: 2023 ASCO Quality Care Symposium; October 27-28, 2023; Boston, MA. Accessed October 24, 2023. https://meetings.asco.org/abstracts-presentations/227883 

Our summary

Oncologists encounter unique challenges in staying current with the latest therapies. Clinical decision support (CDS) tools like Flatiron Assist™ offer real-time access to evolving treatment guidelines. This study explores the prescription patterns of oncologists who utilized Flatiron Assist™ versus those who did not, following the FDA approval and CDS tool incorporation of a new treatment regimen. 

Specifically, the research focuses on the ordering trends related to nivolumab and platinum-doublet chemotherapy in neoadjuvant Non-Small Cell Lung Cancer (NSCLC).

HC image-1Figure. Time to first nivolumab/platinum doublet order post-incorporation in CDS tool. The FDA approved this treatment on March 4, 2022 and updates were incorporated in the CDS tool on April 12, 2022

Why this matters

The study’s findings underscore the significant impact of CDS tools, showing that oncologists utilizing the tool initiated the newly approved treatment 59 days earlier than non-CDS tool users. This early adoption, facilitated by real-time information, has the potential to improve patient outcomes.

Read the research

Share